IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v11y2020i1d10.1038_s41467-020-16505-0.html
   My bibliography  Save this article

Immunogenicity of a DNA vaccine candidate for COVID-19

Author

Listed:
  • Trevor R. F. Smith

    (Inovio Pharmaceuticals, Plymouth Meeting)

  • Ami Patel

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Stephanie Ramos

    (Inovio Pharmaceuticals, Plymouth Meeting)

  • Dustin Elwood

    (Inovio Pharmaceuticals, Plymouth Meeting)

  • Xizhou Zhu

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Jian Yan

    (Inovio Pharmaceuticals, Plymouth Meeting)

  • Ebony N. Gary

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Susanne N. Walker

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Katherine Schultheis

    (Inovio Pharmaceuticals, Plymouth Meeting)

  • Mansi Purwar

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Ziyang Xu

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Jewell Walters

    (Inovio Pharmaceuticals, Plymouth Meeting)

  • Pratik Bhojnagarwala

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Maria Yang

    (Inovio Pharmaceuticals, Plymouth Meeting)

  • Neethu Chokkalingam

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Patrick Pezzoli

    (Inovio Pharmaceuticals, Plymouth Meeting)

  • Elizabeth Parzych

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Emma L. Reuschel

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Arthur Doan

    (Inovio Pharmaceuticals, Plymouth Meeting)

  • Nicholas Tursi

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Miguel Vasquez

    (Inovio Pharmaceuticals, Plymouth Meeting)

  • Jihae Choi

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Edgar Tello-Ruiz

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Igor Maricic

    (Inovio Pharmaceuticals, Plymouth Meeting)

  • Mamadou A. Bah

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Yuanhan Wu

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Dinah Amante

    (Inovio Pharmaceuticals, Plymouth Meeting)

  • Daniel H. Park

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Yaya Dia

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Ali Raza Ali

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Faraz I. Zaidi

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Alison Generotti

    (Inovio Pharmaceuticals, Plymouth Meeting)

  • Kevin Y. Kim

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Timothy A. Herring

    (Inovio Pharmaceuticals, Plymouth Meeting)

  • Sophia Reeder

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Viviane M. Andrade

    (Inovio Pharmaceuticals, Plymouth Meeting)

  • Karen Buttigieg

    (National Infection Service, Public Health England, Porton Down)

  • Gan Zhao

    (Advaccine (Suzhou) Biopharmaceuticals Co., Ltd)

  • Jiun-Ming Wu

    (Advaccine (Suzhou) Biopharmaceuticals Co., Ltd)

  • Dan Li

    (Fudan University)

  • Linlin Bao

    (Fudan University)

  • Jiangning Liu

    (Fudan University)

  • Wei Deng

    (Fudan University)

  • Chuan Qin

    (Fudan University)

  • Ami Shah Brown

    (Inovio Pharmaceuticals, Plymouth Meeting)

  • Makan Khoshnejad

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Nianshuang Wang

    (The University of Texas at Austin)

  • Jacqueline Chu

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Daniel Wrapp

    (The University of Texas at Austin)

  • Jason S. McLellan

    (The University of Texas at Austin)

  • Kar Muthumani

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Bin Wang

    (Fudan University)

  • Miles W. Carroll

    (National Infection Service, Public Health England, Porton Down)

  • J. Joseph Kim

    (Inovio Pharmaceuticals, Plymouth Meeting)

  • Jean Boyer

    (Inovio Pharmaceuticals, Plymouth Meeting)

  • Daniel W. Kulp

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Laurent M. P. F. Humeau

    (Inovio Pharmaceuticals, Plymouth Meeting)

  • David B. Weiner

    (Vaccine and Immunotherapy Center, Wistar Institute)

  • Kate E. Broderick

    (Inovio Pharmaceuticals, Plymouth Meeting)

Abstract

The coronavirus family member, SARS-CoV-2 has been identified as the causal agent for the pandemic viral pneumonia disease, COVID-19. At this time, no vaccine is available to control further dissemination of the disease. We have previously engineered a synthetic DNA vaccine targeting the MERS coronavirus Spike (S) protein, the major surface antigen of coronaviruses, which is currently in clinical study. Here we build on this prior experience to generate a synthetic DNA-based vaccine candidate targeting SARS-CoV-2 S protein. The engineered construct, INO-4800, results in robust expression of the S protein in vitro. Following immunization of mice and guinea pigs with INO-4800 we measure antigen-specific T cell responses, functional antibodies which neutralize the SARS-CoV-2 infection and block Spike protein binding to the ACE2 receptor, and biodistribution of SARS-CoV-2 targeting antibodies to the lungs. This preliminary dataset identifies INO-4800 as a potential COVID-19 vaccine candidate, supporting further translational study.

Suggested Citation

  • Trevor R. F. Smith & Ami Patel & Stephanie Ramos & Dustin Elwood & Xizhou Zhu & Jian Yan & Ebony N. Gary & Susanne N. Walker & Katherine Schultheis & Mansi Purwar & Ziyang Xu & Jewell Walters & Pratik, 2020. "Immunogenicity of a DNA vaccine candidate for COVID-19," Nature Communications, Nature, vol. 11(1), pages 1-13, December.
    • Handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-16505-0
    DOI: 10.1038/s41467-020-16505-0
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-020-16505-0
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-020-16505-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-16505-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.